Profile - To The Moon

Mattcav

Posts · 2Posts · 2
Following · 0Following · 0
Followers · 0Followers · 0

- MattcavMattcav
  ·09-21 18:32
  A
  0 Comment
  1
  Share
  Report
- MattcavMattcav
  ·08-26
  A
  Movement Alert｜Moderna, Inc. Rises 4.3% in Regular Trading, Continued Price Reassessment After Cancer Vaccine Phase III Success
  On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177%...
  Movement Alert｜Moderna, Inc. Rises 4.3% in Regular Trading, Continued Price Reassessment After Cancer Vaccine Phase III Success
  85 Comment
  1
  Share
  Report
No following yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4247036101061202","uuid":"4247036101061202","gmtCreate":1784188769471,"gmtModify":1789987140181,"name":"Mattcav","pinyin":"mattcav","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/062ff39866fdd7bc3706ce44cdfe2b59","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":610140483375904,"gmtCreate":1789986774314,"gmtModify":1789987115791,"author":{"id":"4247036101061202","authorId":"4247036101061202","name":"Mattcav","avatar":"https://community-static.tradeup.com/news/062ff39866fdd7bc3706ce44cdfe2b59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247036101061202","idStr":"4247036101061202"},"themes":[],"title":"","htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/610140483375904","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":600840804271120,"gmtCreate":1787726718486,"gmtModify":1787728379622,"author":{"id":"4247036101061202","authorId":"4247036101061202","name":"Mattcav","avatar":"https://community-static.tradeup.com/news/062ff39866fdd7bc3706ce44cdfe2b59","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4247036101061202","idStr":"4247036101061202"},"themes":[],"title":"","htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/600840804271120","repostId":"1191212087","repostType":2,"repost":{"id":"1191212087","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Market Focus","id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"pubTimestamp":1787664920,"share":"https://ttm.financial/m/news/1191212087?lang=en_US&edition=fundamental","pubTime":"2026-08-25 21:35","market":"us","language":"en","title":"Movement Alert｜Moderna, Inc. Rises 4.3% in Regular Trading, Continued Price Reassessment After Cancer Vaccine Phase III Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1191212087","media":"Market Focus","summary":"On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177%...","content":"<p><p>On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177% surge triggered by the mRNA cancer vaccine Phase III trial success.</p><p>On the news front, Barclays raised its price target on Moderna from $48 to $125, while the stock continues to digest the landmark announcement that its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck, achieved the primary endpoint in the Phase III INTerpath-001 trial for high-risk melanoma. This represents the first mRNA cancer therapy to deliver positive results in a randomized controlled Phase III trial. Multiple Wall Street firms have significantly raised targets, with BofA upgrading to Neutral with a $170 target, Jefferies raising to $150, and Piper Sandler setting $167. The options market reflects extreme volatility with IV percentile at 99.6%, indicating intense bull-bear debate as the stock stabilizes after its initial 23.5% pullback and 16% rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Rises 4.3% in Regular Trading, Continued Price Reassessment After Cancer Vaccine Phase III Success</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Rises 4.3% in Regular Trading, Continued Price Reassessment After Cancer Vaccine Phase III Success\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-25 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177% surge triggered by the mRNA cancer vaccine Phase III trial success.</p><p>On the news front, Barclays raised its price target on Moderna from $48 to $125, while the stock continues to digest the landmark announcement that its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck, achieved the primary endpoint in the Phase III INTerpath-001 trial for high-risk melanoma. This represents the first mRNA cancer therapy to deliver positive results in a randomized controlled Phase III trial. Multiple Wall Street firms have significantly raised targets, with BofA upgrading to Neutral with a $170 target, Jefferies raising to $150, and Piper Sandler setting $167. The options market reflects extreme volatility with IV percentile at 99.6%, indicating intense bull-bear debate as the stock stabilizes after its initial 23.5% pullback and 16% rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191212087","content_text":"On August 25, Moderna, Inc. rose 4.3% in regular trading, trading at $148.99/share, with turnover of $397 million. The stock remains in a volatile price reassessment phase following its historic 177% surge triggered by the mRNA cancer vaccine Phase III trial success.On the news front, Barclays raised its price target on Moderna from $48 to $125, while the stock continues to digest the landmark announcement that its personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck, achieved the primary endpoint in the Phase III INTerpath-001 trial for high-risk melanoma. This represents the first mRNA cancer therapy to deliver positive results in a randomized controlled Phase III trial. Multiple Wall Street firms have significantly raised targets, with BofA upgrading to Neutral with a $170 target, Jefferies raising to $150, and Piper Sandler setting $167. The options market reflects extreme volatility with IV percentile at 99.6%, indicating intense bull-bear debate as the stock stabilizes after its initial 23.5% pullback and 16% rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","news_type":1,"symbols_score_info":{"MRNA":1}},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}